Open Mic: Next in Health series

As bioconvergence reshapes the life sciences, the move from animal models to human-relevant technologies is gaining momentum.

In this edition of our Open Mic: Next in Health series, experts from biopharma will discuss how advanced in vitro models – such as organoids and microphysiological systems – are changing the way we approach preclinical testing.

While organoids provide more accurate, human-like biology, they also bring challenges in consistency, scalability, and workflow integration. Our panel will explore how automation, bioengineering, and AI are helping overcome these barriers and enabling wider use of organoid-based models in drug research.

At the same time, regulators are beginning to recognize and support these new approaches, paving the way for broader adoption in drug development.

Together, these shifts mark an exciting moment for preclinical science – where biology, technology, and policy come together to create more human-focused and effective research.

Our panelists at this event bring deep expertise and diverse perspectives on this topic:

• Gilles Weder, Head Research & BD, Life Science Technologies, CSEM
• Annie Moisan, Discovery Area Leader, Nephrology, Roche
• Dominic Hoepfner, Functional Genomics Group, Novartis Biomedical Research
• Jan Lichtenberg, CEO, InSphero AG

Whether you’re a healthcare innovator, clinician, researcher, or policymaker, this session will offer valuable insights into technology in preclinical testing. Register early to avoid missing out!

Participation is free; however, registration is required before 3 Nov 2025 (onsite)